Hemorrhagic Stroke Initiative

This American Heart Association® initiative, sponsored by AstraZeneca, addresses the need for improved identification and treatment of hemorrhagic stroke patients.

The Hemorrhagic Stroke Initiative is evaluating new efforts to enhance the care of hemorrhagic stroke patients in hospitals and stroke centers across America.

Stroke is the No. 5 cause of death in the United States and a leading cause of disability. Hemorrhagic strokes make up roughly 10 percent of the nearly 800,000 strokes that occur annually, and they have a higher mortality rate than other types of stroke. Hemorrhagic stroke patients who are treated with novel oral anticoagulants, or NOACs, have an in-hospital mortality rate of 26.5%.

Built on the foundation of Get With The Guidelines®

The ICH Initiative began in response to the 2018 Clinical Performance Measures for Adults Hospitalized With Intracerebral Hemorrhage: Performance Measures for Healthcare Professionals From the American Heart Association/ American Stroke Association(link opens in new window). Built within the Get With The Guidelines program, this initiative leverages the hospital-based quality improvement program from provide tools and resources that increase adherence to the latest research-based guidelines. 

See below for the 2022 Guideline Update regarding Intracerebral Hemorrhage. For professional education regarding this guideline, we've assembled a supporting presentation for internal hospital use.